Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EGFR T790M”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableStudy completedNCT03133234
What this trial is testing

Effect of Osimertinib in Ethnic Chinese With EGFR and T790M Mutated NSCLC

Who this might be right for
T790M Positive NSCLC Patients
AstraZeneca 47
Early research (Phase 1)Ended earlyNCT04622072
What this trial is testing

XZP-5809-TT1 Tablets in Patients With T790M Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer
Sihuan Pharmaceutical Holdings Group Ltd. 21
Testing effectiveness (Phase 2)Study completedNCT03810066
What this trial is testing

Exploring the Theragnostic Value of Osimertinib in EGFR-mutated Lung Cancer (THEROS)

Who this might be right for
NSCLCEGFR T790MFDG-PET
University Hospital, Essen 16
Testing effectiveness (Phase 2)UnknownNCT02811354
What this trial is testing

Phase II Study of AZD9291 in Advanced Stage NSCLC With EGFR and T790M Mutations Detected in Plasma Ct-DNA

Who this might be right for
Carcinoma, Non-Small-Cell Lung
National University Hospital, Singapore 108
Testing effectiveness (Phase 2)Study completedNCT02489903
What this trial is testing

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

Who this might be right for
Small Cell CarcinomaCarcinoma, Non-Small-Cell LungNeuroendocrine Tumors+1 more
EpicentRx, Inc. 139
Testing effectiveness (Phase 2)UnknownNCT03300115
What this trial is testing

Clinical Trial of the Efficacy and Safety of AC0010 in the Treatment of EGFR T790M Patients With Advanded NSCLC

Who this might be right for
Metastatic Non-small Cell Lung Cancer
Hangzhou ACEA Pharmaceutical Research Co., Ltd. 222
Not applicableStudy completedNCT03457220
What this trial is testing

An Observational Study to Evaluate AZD9291 Treatment in Patients With T790M Positive Non-small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer
AstraZeneca 423
Not applicableApproved For MarketingNCT04829422
What this trial is testing

Early Access Program of Lazertinib in Republic of Korea

Who this might be right for
Lung Cancer
Yuhan Corporation
Early research (Phase 1)Study completedNCT02923947
What this trial is testing

Study to Assess Osimertinib in Patients w/ Adv Solid Tumours & Normal Kidney Function or Severe Kidney Impairment

Who this might be right for
Solid Tumours
AstraZeneca 16
Early research (Phase 1)Ended earlyNCT04510415
What this trial is testing

Olmutinib 600 mg QD in Patients With T790M-positive NSCLC After Treatment With an EGFR-TKI

Who this might be right for
Non Small Cell Lung Cancer
Hanmi Pharmaceutical Company Limited 2
Not applicableEnded earlyNCT02405247
What this trial is testing

TAURAS - T790 AURA ScreenFailure SOC Registry Study

Who this might be right for
Non Small Cell Lung Cancer
AstraZeneca 400
Not applicableStudy completedNCT01734915
What this trial is testing

Detecting EGFR T790M Mutations From Circulating Tumor Cells

Who this might be right for
Non Small Cell Lung Cancer
Massachusetts General Hospital 40
Testing effectiveness (Phase 2)UnknownNCT05701384
What this trial is testing

Lazertinib 160mg in EGFR T790M NSCLC

Who this might be right for
Lung Cancer Stage IVEGFR T790M
Samsung Medical Center 117
Large-scale testing (Phase 3)UnknownNCT01579630
What this trial is testing

Genius Study Study to Compare Efficacy and Safety of Gefitinib/ Pemetrexed With Pemetrexed Alone as Maintenance Therapy in Patients With Stage IV EGFR Mutation Negative or T790M Single Mutation Who Respond to Pemetrexed/ Platinum as First-line Therapy

Who this might be right for
NSCLC
Taipei Veterans General Hospital, Taiwan 52
Large-scale testing (Phase 3)UnknownNCT05209256
What this trial is testing

Alflutinib Versus Alflutinib Plus Chemotherapy for NSCLC

Who this might be right for
NSCLC
The First Affiliated Hospital of Henan University of Science and Technology 90
Testing effectiveness (Phase 2)UnknownNCT03758677
What this trial is testing

Apatinib Combined With Chemotherapy for NSCLC Patients Without T790M Mutation

Who this might be right for
Non Small Cell Lung Cancer
The First Hospital of Jilin University 30
Testing effectiveness (Phase 2)Study completedNCT03228277
What this trial is testing

Olmutinib Trial in T790M (+) NSCLC Patients Detected by Liquid Biopsy Using BALF Extracellular Vesicular DNA

Who this might be right for
Non Small Cell Lung Cancer
Konkuk University Medical Center 25
Testing effectiveness (Phase 2)Active Not RecruitingNCT06303167
What this trial is testing

Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more
National Cancer Institute (NCI) 19
Testing effectiveness (Phase 2)Study completedNCT02759835
What this trial is testing

Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib

Who this might be right for
Lung AdenocarcinomaLung Neoplasms
National Cancer Institute (NCI) 37
Testing effectiveness (Phase 2)UnknownNCT05498389
What this trial is testing

EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer

Who this might be right for
Metastatic Lung Non-Small Cell CarcinomaAdvanced Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8+6 more
Shanghai EpimAb Biotherapeutics Co., Ltd. 115
Next Page